Uses of Epoetin for Anemia in OncologyAgency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2001 - Health & Fitness - 330 pages |
From inside the book
Results 1-5 of 47
Page vi
Anemia primarily a result of malignancy included patients with multiple myeloma , non- Hodgkin's lymphoma , chronic lymphocytic leukemia , and myelodysplastic syndromes . Epoetin increases Hb levels and achieves statistically ...
Anemia primarily a result of malignancy included patients with multiple myeloma , non- Hodgkin's lymphoma , chronic lymphocytic leukemia , and myelodysplastic syndromes . Epoetin increases Hb levels and achieves statistically ...
Page 9
... ( multiple myeloma , non - Hodgkin's lymphoma , chronic lymphocytic leukemia , and myelodysplastic syndromes - MDS ) . With the exception of one trial on patients with MDS , the preponderance of patients in these trials received ...
... ( multiple myeloma , non - Hodgkin's lymphoma , chronic lymphocytic leukemia , and myelodysplastic syndromes - MDS ) . With the exception of one trial on patients with MDS , the preponderance of patients in these trials received ...
Page 10
... multiple myeloma or non - Hodgkin's lymphoma , irrespective of history of prior transfusion . A single study of MDS patients reported that epoetin increases hematologic responses for patients without previous history of transfusion but ...
... multiple myeloma or non - Hodgkin's lymphoma , irrespective of history of prior transfusion . A single study of MDS patients reported that epoetin increases hematologic responses for patients without previous history of transfusion but ...
Page 18
... ( multiple myeloma , non- Hodgkin's lymphoma , chronic lymphocytic leukemia ) or myelodysplastic syndrome ( MDS ) . Objectives For the two groups of patients above , this 18 Anemia Primarily Due to Cancer Therapy and Anemia Due Malignant ...
... ( multiple myeloma , non- Hodgkin's lymphoma , chronic lymphocytic leukemia ) or myelodysplastic syndrome ( MDS ) . Objectives For the two groups of patients above , this 18 Anemia Primarily Due to Cancer Therapy and Anemia Due Malignant ...
Page 24
... multiple myeloma , lymphoma , and prostate , breast , and small cell lung cancer ( Abels , 1992 ; Frenkel , Bick , and Rutherford , 1996 ; Rappeport and Bunn , 1994 ) . Myelofibrosis and other nonmalignant processes that replace the ...
... multiple myeloma , lymphoma , and prostate , breast , and small cell lung cancer ( Abels , 1992 ; Frenkel , Bick , and Rutherford , 1996 ; Rappeport and Bunn , 1994 ) . Myelofibrosis and other nonmalignant processes that replace the ...
Common terms and phrases
adverse events allogeneic analysis Assessment autologous blood bone marrow ablation bone marrow transplantation Boogaerts Bukowski cancer patients Cella characteristics of epoetin chemotherapy Citation clinical compared control arms controlled trials disease dosing regimen effect of epoetin enrolled patients epoetin administration epoetin alfa epoetin arm epoetin dose epoetin treatment epoetin-treated patients Evaluable Evidence Table fatigue Fauser g/dL GM-CSF Hb threshold Hematol hematologic malignancies hematologic response hemoglobin higher quality studies initiating epoetin Lookup managing anemia mean Hb Mean/Median Baseline Hb median multiple myeloma myelodysplastic syndromes nonrandomized number of patients Oncology Osterborg patients transfused pediatric Pedrazzoli percent percentage of patients Placebo Placebo control quality-of-life radiation therapy radiotherapy randomized randomized controlled trials RBC engraftment RBC transfusion RBC units transfused recombinant human erythropoietin reticulocyte significant difference Silvestris stem cells stem-cell transplant studies reported study arms subcutaneous systematic review transfused per patient transfusion outcomes treatment duration U/kg per week unblinded Value Vannucchi ΙΕΡΟ